Ridinilazole fell short of significance in a late-stage trial, with some analysts now anticipating the company will alter its therapeutic strategy entirely.

What on earth would make a biotech company change the primary endpoint half way through a Phase III program and not discuss it with the FDA? There are at least two scenarios, neither of them good.

Public Company Edition: There was just one initial public offering during the past two weeks, but another biotech-focused SPAC went public and Gingko Bioworks announced a high-value SPAC merger. Also, Insmed and Dynavax offerings led recent public company financings.

Destiny Pharma's XF-73 achieved an "exceptionally high" 99.5% reduction in Staphylococcus aureus bacterial nasal carriage in a mid-stage trial, a result that should attract a number of potential partners for the UK firm.